Approval · Notice of Compliance 26225 · 2021
AGRYLIN: Notice of Compliance 26225
Issued July 7, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26225
- Date
- July 7, 2021
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Update the Product Monograph to the 2020 format Administrative: Merger/Buy-out
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AGRYLIN | 02236859 | Cancelled Post Market |
Medicinal ingredients
- ANAGRELIDE HYDROCHLORIDE 0.5 MG per CAP